Although elective PCI for most low-risk patients is extremely safe, overnight observation is still standard practice in the U.S., largely due to the lack of evidence demonstrating that same-day discharge is safe. Now a new meta-analysis, published online in the Journal of the American College of Cardiology, provides support for same-day discharge in carefully selected…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

John Ryan interviews Stacie Daugherty, lead author of a study recently published online by JACC on differences in rates of bleeding and bleeding avoidance strategies (BAS) between women and men undergoing PCI. THE STUDY Investigators used data from the CathPCI registry to analyze the use of BAS (radial access, bivalirudin, vascular closure devices, or any…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

This week’s topics include an article on open science through data sharing, primary prevention of CVD with a Mediterranean diet, atherosclerosis found in mummies, and more.

This week’s topics include the TACT study of chelation therapy, off-pump vs. on-pump CABG, clopidogrel with or without aspirin in those taking oral anticoagulants and undergoing PCI, and more.

Brahmajee Nallamothu discusses his study group’s analysis comparing the accuracy of visually interpreted coronary angiography and quantitative coronary angiography.

Deepak Bhatt sheds light on findings from the CHAMPION PHOENIX trial and their implications for clinical practice.

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. In the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) trial, the intravenous…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

This week’s topics include extended use of apixaban, dabigatran, warfarin, or placebo in VTE, the 5-year follow-up of the SYNTAX study, and more.

The 5 year results of the SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery) trial are now published.  SYNTAX assessed the optimal revascularization strategy for patients with left main and/or 3-vessel disease by randomly assigning such patients to CABG or PCI (with a first-generation paclitaxel-eluting stent) and then determining the rate of…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

According to the recently published results of the WOEST trial, patients receiving anticoagulation thereapy who undergo stenting have better outcomes with clopidogrel only than with clopidogrel plus aspirin. Rick Lange and David Hillis ask: Are you ready to stop prescribing aspirin to these patients?